Gavi provides one-time cash grants to bridge the resource gap at the time of vaccine introduction and allow critical activities to be conducted in a timely manner
In June 2016 the Gavi Board approved the Health System and Immunisation Strengthening (HSIS) Support Framework. HSIS includes long-term health system strengthening (HSS) support as well as one-time grants to cover a part of the operational cost of new vaccine introductions, vaccination campaigns, and vaccine product switches.
The HSIS Support Framework will be effective January 2017. At that time, the Vaccine Introduction Grant and Operational Support for Campaigns Policy will no longer be effective.
The introduction of a new vaccine into a country’s routine immunisation system requires careful planning and preparation. Gavi provides a cash grant to countries ahead of each new vaccine introduction in order to support important activities before the launch.
Gavi also provides support for the delivery of campaigns. These two types of grants represent one-time Gavi investments expected to cover a share of necessary activities with the remainder being funded by the Government and partners, if necessary.
What is the purpose of Gavi’s vaccine introduction grants?
The aim of Gavi’s vaccine introduction grant is to facilitate the
timely and effective implementation of critical activities in the
national vaccine introduction plan in advance of a new vaccine
introduction. The grant is mostly used by countries to support a share
of the cost of pre-introduction activities such as health worker
training, information, education and communication (IEC) and social
mobilisation, expansion or rehabilitation of some cold chain equipment
and additional vehicles, or technical assistance.
What is the purpose of Gavi’s operational support for campaigns?
Besides funding the vaccines for large scale campaigns, Gavi
provides cash support to help countries cover a share of the operational
cost for delivering these campaigns. The aim of this type of support is
to facilitate the timely and effective delivery of vaccines to the
In addition to
the pre-introduction activities outlined above, countries can use this
allocation to pay for health workers and supervisor per diems, volunteer
incentives, additional cold chain equipment, transport, monitoring and
evaluation and civil society organisation and/or volunteer incentives
for social mobilisation.
How much support does Gavi provide?
Vaccine Introduction Grants
For vaccines delivered to infants
$0.80 per child in the birth cohort
Or minimum lump sum of $100,000
For HPV vaccines
$2.40 per girl
Or minimum lump sum of $100,000
Operational support for campaigns
All Gavi supported campaigns
$0.65 per target person
When is the policy applied and how does it work?
The policy is applied to all new introductions of Gavi supported
vaccines into a country’s routine immunisation system and to all Gavi
supported campaigns. Countries apply for these grants as part of their
normal application for vaccine support to Gavi. Countries provide a
budgeted plan of the specific activities to be funded with this money
and must report on the use of the grants in their annual progress
reports to Gavi.
After approval for
support, a country may be requested or wish to change the original
formulation and/or presentation of a vaccine containing the same
antigen(s). To facilitate transition to a new product, countries can
apply for a small additional grant (one third of an introduction grant)
if specific criteria are met.
All grants are subject to fiduciary oversight measures as per Gavi’s Transparency and Accountability Policy.
When was the policy approved and when will it be updated?
Gavi has disbursed vaccine introduction grants since 2001. The
policy was first reviewed and revised in 2007. Based on a second review
in 2011/2012, the Gavi Board approved the new vaccine introduction grant
and operational support for campaigns policy in June 2012. The new
policy comes into effect as of September 1, 2012, and will apply to all
new vaccine introductions and campaigns taking place after this date.
The next full review of the policy is scheduled for 2017.